CRVS - Corvus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.46
+0.02 (+0.21%)
As of 11:57AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close9.44
Open9.47
Bid9.44 x 1200
Ask9.47 x 800
Day's Range9.25 - 10.04
52 Week Range7.42 - 17.30
Volume196,992
Avg. Volume78,031
Market Cap276.212M
Beta-2.05
PE Ratio (TTM)N/A
EPS (TTM)-2.18
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • Associated Press2 months ago

    Corvus: 2Q Earnings Snapshot

    On a per-share basis, the Burlingame, California-based company said it had a loss of 40 cents. Corvus shares have fallen 9 percent since the beginning of the year. In the final minutes of trading on Thursday, ...

  • GlobeNewswire2 months ago

    Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the second quarter ended June 30, 2018, and provided a business update. “We continue to be a leader in programs addressing the adenosine pathway, with three clinical trials currently enrolling and more than 235 patients treated to-date with our lead product candidate, an A2A receptor antagonist, CPI-444,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “We are enrolling up to 50 patients in a Phase 1/1b study of CPI-444 in combination therapy under an amended protocol focused on patients with earlier stage renal cell cancer.

  • GlobeNewswire2 months ago

    Corvus Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

    BURLINGAME, Calif., July 31, 2018-- Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today ...

  • GlobeNewswire3 months ago

    Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced publication of results of preclinical studies of CPI-444 conducted by researchers at Johns Hopkins University School of Medicine. The data showed that CPI-444 administered as monotherapy suppressed tumor growth and improved survival in animal tumor models, and CPI-444 administered in combination with anti-PD-1 therapy dramatically improved antitumor immune responses over either agent used alone. The results were published online this month in the journal Cancer Immunology, Immunotherapy (CII), in a publication titled “Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT (adoptive cellular therapy) in murine cancer models,” and can be accessed here.

  • Associated Press5 months ago

    Corvus: 1Q Earnings Snapshot

    On a per-share basis, the Burlingame, California-based company said it had a loss of 63 cents. Corvus shares have decreased 9 percent since the beginning of the year. In the final minutes of trading on ...

  • ACCESSWIRE6 months ago

    Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting

    Stock Monitor: Corvus Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ...

  • Associated Press7 months ago

    Corvus reports 4Q loss

    On a per-share basis, the Burlingame, California-based company said it had a loss of 58 cents. For the year, the company reported that its loss widened to $55.7 million, or $2.72 per share. Corvus shares ...